We are live on ! Find out more
CYTK icon

Cytokinetics

347 hedge funds and large institutions have $9.5B invested in Cytokinetics in 2023 Q4 according to their latest regulatory filings, with 101 funds opening new positions, 76 increasing their positions, 108 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

339% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 23

100% more funds holding in top 10

Funds holding in top 10: 10 → 20 (+10)

78% more call options, than puts

Call options by funds: $1.4B | Put options by funds: $787M

39% more funds holding

Funds holding: 250 → 347 (+97)

25% more capital inflows, than outflows

Capital inflows: $647M | Capital outflows: $518M

0.49% less ownership

Funds ownership: 111.45% → 110.96% (-0.49%)

30% less repeat investments, than reductions

Existing positions increased: 76 | Existing positions reduced: 108

Holders
347
Holders Change
+97
Holders Change %
+38.8%
% of All Funds
5.05%
Holding in Top 10
20
Holding in Top 10 Change
+10
Holding in Top 10 Change %
+100%
% of All Funds
0.29%
New
101
Increased
76
Reduced
108
Closed
23
Calls
$1.4​B
Puts
$787​M
Net Calls
+$611​M
Net Calls Change
+$639​M

CYTK Hedge Fund Activity: Q4 2023 in Review

347 of the 6,876 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q4 2023, worth a combined $9.5B — up 196% from $3.22B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CYTK positions and 23 closed out — a net gain of 78 holders — while 76 added to existing stakes and 108 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $80.8M. The largest seller was Wellington Management Group, cutting an estimated $54.2M.

  • 347 institutional investors held Cytokinetics (CYTK) as of Q4 2023, up from 250 in Q3 2023.
  • Funds reported $9.5B of Cytokinetics stock for Q4 2023, up 196% quarter-over-quarter.
  • 101 funds opened new Cytokinetics positions in Q4 2023 and 23 closed out, a net change of +78 holders.
  • The largest Cytokinetics buyer in Q4 2023 was T. Rowe Price Associates, an estimated $80.8M added.
  • The largest Cytokinetics seller in Q4 2023 was Wellington Management Group, an estimated $54.2M sold.

Based on aggregated 13F filings for Q4 2023.